Jorge Luis López García
Marketeer - Enthusiastic Team Leader And Business Developer
CDMX
Summary
Passionate and results-driven pharmaceutical executive with 20+ years of commercial leadership across top global pharmaceutical companies, driving growth in oncology, hematology, rare diseases, specialty care and primary care. Proven track record leading sales and marketing teams, managing full product lifecycles, accelerating launches, turning around mature brands, and delivering sustained P&L impact. Experienced in private/public markets, access strategy, diagnostic pathway optimization and cross-functional execution. Most recently led AstraZeneca Lung Cancer BU, scaling targeted therapies, Immuno-oncology and antibody-drug conjugates through strategy, seamless execution and team’s transformational growth.
Overview
25
25
years of professional experience
2
2
Certifications
2
2
Languages
Work History
Business Unit Manager | Lung Cancer Franchise
AstraZeneca
03.2023 - 11.2025
- Franchise Leader for Lung Cancer, guiding the highest-growth business unit within AstraZeneca's Oncology division.
- Successfully managing a robust marketing and sales team and expanding portfolio of cutting-edge solutions in this crucial therapeutic area.
- Delivered 100% CAGR (’23–’25) for the whole Lung Cancer franchise by orchestrating unified commercial, marketing, access, medical and diagnostic execution across 30+ cross-functional members.
- Drove Tagrisso to $60M USD sales, 75%+ MS and 63% YoY growth (’25 vs ’24) by expanding public-sector demand, increasing coverage for private market patients, and launching 3 new indications in two years.
- Scaled Imfinzi to $20M USD, achieving 115% YoY growth, accelerating uptake via patient acquisition programs, affordability initiatives and first IMSS/ISSSTE contracts despite being 4th-to-market in IO; 3 new indications launched since 2023.
- Strengthened early diagnosis by leading the Lung Ambition Alliance (LAA) nationwide, driving AI adoption at institutions, referral optimization and public policy engagement to expand reimbursement pathways.
- Ensured organizational readiness for 6 new indications and 2 new product launches, aligning Medical, Access, Sales and Marketing on strategic and operational execution.
- Designed and scaled a high-specialty field model for EGFR-targeted therapies and immuno-oncology by architecting a dual commercial-diagnostics structure (sales + LAA), doubling field capacity in 2.5 years and enabling earlier patient identification, accelerated uptake and sustained franchise growth.
Commercial Manager | Hematology and Neurofibromatosis type 1 (NF1)
AstraZeneca
08.2021 - 03.2023
- Leader of hematology business unit (sales and marketing) and NF1 product launch strategy.
- Led the Hematology BU to 125% YoY growth (’22 vs ’21) through integrated commercial strategy for Calquence (MCL/CLL), including field redesign, new diagnostic programs and expanded deployment.
- Launched the first IMSS-specific patient program for Calquence, securing 15 new patients and sustaining double-digit private market growth (E.I. 160% YE’22).
- Designed and launched Mexico’s most comprehensive CLL diagnostic program, improving identification and conversion of eligible patients.
- Successfully launched Koselugo, AstraZeneca first rare disease product, via a fully remote omnichannel model, meeting 100% of 2022 targets.
Regional First Line Sales Manager | Hematology and Oncology - Northwest / Center and South Mexico
Novartis Oncology
10.2018 - 08.2021
- Achieved +80% YoY growth (2019) in Breast Cancer, delivering 60% of national sales from a region representing only 40% of Mexico’s population.
- Reached 110% sales budget (2020) in Hematology and reached 70% MS in Immune Thrombocytopenia (ITP) in the Center/South region.
- Reduced Travel & Expenses by 25% through territory optimization and resource realignment, increasing synergy across two BUs.
- Maintained business continuity and growth during COVID-19 via hybrid leadership models and execution reinforcement.
- Strengthened performance management, account planning and segmentation to maximize portfolio uptake.
Sr. Product Manager | Hematology (Immune Thrombocytopenia, Myelofibrosis, Iron Overload) - Mexico, Central America and Caribbean
Novartis Oncology
01.2013 - 09.2018
- Accelerated Revolade via private-market penetration and other government institution strategy: +39% sales vs 2016 and 65% MS.
- Co-led access strategy securing reimbursement for new ITP indications (sAA, pediatric ITP) across IMSS, ISSSTE and national institutions.
- Revitalized Exjade via repositioning and new demand generation: +13% growth, +20% IMSS demand, forecast accuracy to 90%.
- Expanded Jakavi in MF/PV across private/public/insurer channels, delivering +65% growth vs 2014.
- Added MC3 responsibilities (2018), aligning strategy with Costa Rica, Panama and Dominican Republic.
Business franchise head Ad-Interim | Hematology unit - Mexico, Central America and Caribbean
Novartis Oncology
02.2018 - 07.2018
- Led the hematology franchise across Mexico and MC3 during a transition period, directing 2 PMs, 2 Sales Managers and 17 field reps, ensuring operational continuity, stable performance KPIs and coordinated marketing/sales alignment.
Product Manager | Specialty Care, Dermatology & Anti-Inflammatories
Roche
01.2004 - 09.2013
- Specialty Care - Renal Anaemia & Transplants (2008): Led four-brand portfolio generating $550M MXN+ and 121% budget achievement (2012); strengthened Anaemia franchise to 42.7% MS and doubled Valcyte sales (2012 vs 2008); coordinated 137 reps across PC & SC.
- Dermatology (2006): Launched Protopic, reaching 30% MS despite early generic entry; grew Roaccutan from 45% to 62% MS post-LoE.
- Anti-Inflammatories (2004): Turned around Febrax performance, halting multi-year decline with 20% less budget and managing 220+ reps, making it one of the most profitable PC brands.
Product Associate | Primary Care
Roche
05.2002 - 12.2003
- Supported brand management, tactical execution, market research, and field alignment across analgesic and anti-inflammatory products.
Sales Representative | Primary Care
Roche
08.2000 - 04.2002
- Delivered strong in-field performance across priority brands, consistently exceeding coverage and activity KPIs.
Education
Postgraduate Diploma - Marketing
Universidad Tecnológica De México
Mexico City01.2004
Bachelor of Business Administration in Marketing - Marketing
Universidad Tecnológica De México
Mexico City09-1998
Skills
Cross-functional team coordination
Certification
Certificate in Strengths Based Leadership and Coaching, Universidad LaSalle & Gallup
Timeline
Business Unit Manager | Lung Cancer Franchise
AstraZeneca
03.2023 - 11.2025
Commercial Manager | Hematology and Neurofibromatosis type 1 (NF1)
AstraZeneca
08.2021 - 03.2023
Regional First Line Sales Manager | Hematology and Oncology - Northwest / Center and South Mexico
Novartis Oncology
10.2018 - 08.2021
Business franchise head Ad-Interim | Hematology unit - Mexico, Central America and Caribbean
Novartis Oncology
02.2018 - 07.2018
Sr. Product Manager | Hematology (Immune Thrombocytopenia, Myelofibrosis, Iron Overload) - Mexico, Central America and Caribbean
Novartis Oncology
01.2013 - 09.2018
Product Manager | Specialty Care, Dermatology & Anti-Inflammatories
Roche
01.2004 - 09.2013
Product Associate | Primary Care
Roche
05.2002 - 12.2003
Sales Representative | Primary Care
Roche
08.2000 - 04.2002
Postgraduate Diploma - Marketing
Universidad Tecnológica De México
Bachelor of Business Administration in Marketing - Marketing
Universidad Tecnológica De México